Worldwide appraisal and update (2010) of telavancin activity tested against a collection of Gram-positive clinical pathogens from five continents |
| |
Authors: | Mendes Rodrigo E Sader Helio S Farrell David J Jones Ronald N |
| |
Institution: | JMI Laboratories, North Liberty, Iowa, USA. |
| |
Abstract: | A total of 15,480 Gram-positive pathogens were collected from 89 sites in the United States, Europe, the Asia-Pacific region, and Latin America in 2010. Telavancin was active against indicated Staphylococcus aureus (MIC(50/90), 0.12/0.25 μg/ml), vancomycin-susceptible Enterococcus faecalis (MIC(50/90), 0.5/0.5 μg/ml), and beta-hemolytic (MIC(50/90), 0.06/0.12 μg/ml) and viridans group streptococcus (MIC(50/90), 0.03/0.06 μg/ml) isolates. These MIC results showed potency for telavancin equal to or greater than that of comparators. These in vitro data confirm a continued potent activity of telavancin when tested against contemporary Gram-positive clinical isolates. |
| |
Keywords: | |
本文献已被 PubMed 等数据库收录! |
|